Xponance Inc. lifted its stake in shares of Bunge Global SA (NYSE:BG – Free Report) by 39.0% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 43,140 shares of the basic materials company’s stock after acquiring an additional 12,104 shares during the period. Xponance Inc.’s holdings in Bunge Global were worth $4,606,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the stock. Mather Group LLC. boosted its stake in Bunge Global by 12.4% in the 2nd quarter. Mather Group LLC. now owns 843 shares of the basic materials company’s stock worth $86,000 after buying an additional 93 shares during the last quarter. RFG Advisory LLC boosted its stake in Bunge Global by 3.9% in the 1st quarter. RFG Advisory LLC now owns 2,589 shares of the basic materials company’s stock worth $265,000 after buying an additional 96 shares during the last quarter. Blue Trust Inc. boosted its stake in Bunge Global by 52.3% in the 2nd quarter. Blue Trust Inc. now owns 297 shares of the basic materials company’s stock worth $30,000 after buying an additional 102 shares during the last quarter. CWM LLC boosted its stake in Bunge Global by 4.1% in the 1st quarter. CWM LLC now owns 2,778 shares of the basic materials company’s stock worth $285,000 after buying an additional 110 shares during the last quarter. Finally, Ballentine Partners LLC boosted its stake in Bunge Global by 2.0% in the 2nd quarter. Ballentine Partners LLC now owns 5,761 shares of the basic materials company’s stock worth $615,000 after buying an additional 111 shares during the last quarter. Institutional investors and hedge funds own 86.23% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Citigroup lowered Bunge Global from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $125.00 to $114.00 in a research note on Thursday, August 1st. Four equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, Bunge Global has a consensus rating of “Moderate Buy” and a consensus price target of $118.00.

Check Out Our Latest Research Report on BG

Bunge Global Stock Performance

NYSE BG opened at $97.12 on Wednesday. The firm has a market capitalization of $13.75 billion, a P/E ratio of 7.82 and a beta of 0.65. Bunge Global SA has a 1-year low of $86.10 and a 1-year high of $114.92. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.03 and a quick ratio of 0.97. The business’s 50-day simple moving average is $101.06 and its 200-day simple moving average is $103.24.

Bunge Global (NYSE:BG – Get Free Report) last released its quarterly earnings data on Wednesday, July 31st. The basic materials company reported $1.73 earnings per share for the quarter, missing the consensus estimate of $1.79 by ($0.06). The firm had revenue of $13.24 billion during the quarter, compared to analyst estimates of $14.30 billion. Bunge Global had a net margin of 2.33% and a return on equity of 14.84%. The business’s revenue for the quarter was down 12.0% on a year-over-year basis. During the same period in the prior year, the firm earned $3.72 earnings per share. Equities analysts predict that Bunge Global SA will post 9.3 EPS for the current year.

About Bunge Global

(Free Report)

Bunge Global SA operates as an agribusiness and food company worldwide. It operates through four segments: Agribusiness, Refined and Specialty Oils, Milling, and Sugar and Bioenergy. The Agribusiness segment purchases, stores, transports, processes, and sells agricultural commodities and commodity products, including oilseeds primarily soybeans, rapeseed, canola, and sunflower seeds, as well as grains comprising wheat and corn; and processes oilseeds into vegetable oils and protein meals.

Read More

• Five stocks we like better than Bunge Global
• Stock Market Sectors: What Are They and How Many Are There? 
• Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
• 3 Healthcare Dividend Stocks to Buy
• Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
• How to Know if a Stock Pays Dividends and When They Are Paid Out
• Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges

Want to see what other hedge funds are holding BG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bunge Global SA (NYSE:BG – Free Report).

Receive News & Ratings for Bunge Global Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bunge Global and related companies with MarketBeat.com’s FREE daily email newsletter.